The global market for cancer diagnostics & technology is expected to grow rapidly owing to the rising awareness relating to cancer and its causes, expanding support by government as far as novel activities and financing, and the expanding healthcare consumption are additionally supporting the development of this market altogether. Going ahead, the approach of non-obtrusive screening systems and new diagnostic biomarkers are anticipated to open new income streams for market players sooner rather than later. However, the nonattendance of an appropriate repayment situation and the absence of talented experts in developing economies may obstruct the market throughout the following couple of years, reports the examination.
The global cancer diagnostics & technology market is segmented based on type of technology, application and geography.
Based on technology, the cancer diagnostics market is categorised into platform-based and instrument-based. Platform-based technology consists of Polymerase Chain Reaction (PCR), In Situ Hybridization (ISH), Immunohistochemistry (IHC), Next Generation Sequencing (NGS), Dna Microarrays, Flow Cytometry. Whereas, instrument-based technology includes imaging and biopsy. Imaging is further sub-segmented into Magentic Resonance Imaging (MRI), Computed Tomography (CT), Positron Emission Tomography- Computed Tomography (PET-CT), Mammography and Ultrasound. The instrument-based segment is expected to hold a major share of the cancer diagnostics market in 2019.
Based on application, the global cancer diagnostics market is segmented into lung cancer, breast cancer, colorectal cancer, melanoma and others. Breast cancer application is relied upon to represent a noteworthy offer of the cancer diagnostics market, by application in 2019. Breast cancer application is anticipated to have a significant share of the cancer diagnostics and technology market during the forecast period.
The global cancer diagnostics & technology market is studied across key regions like North America, Europe, Asia Pacific, and Rest of the World. North America is anticipated to represent the biggest market share in the cancer diagnostics market, trailed by Europe and Asia. However, the Asian market is slated to develop at the highest CAGR in the coming five years and fills in as an income stash for the organizations working in the malignancy diagnostics showcase.
Some of the major players operating in the cancer diagnostics & technology market include Agilent Technologies, Inc., Thermo Fisher Scientific, Inc., Illumina, Inc., Becton, Dickinson and Company, GE Healthcare, QIAGEN N.V., Abbott Laboratories, Inc., Roche Diagnostics, Siemens Healthcare, Philips Healthcare, C.R. Bard, Inc.
Why to buy this report: